BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $12.64 billion. The enterprise value is $15.97 billion.
| Market Cap | 12.64B |
| Enterprise Value | 15.97B |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 193.57 million shares outstanding. The number of shares has increased by 0.61% in one year.
| Current Share Class | 193.57M |
| Shares Outstanding | 193.57M |
| Shares Change (YoY) | +0.61% |
| Shares Change (QoQ) | -1.62% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 101.09% |
| Float | 192.39M |
Valuation Ratios
The trailing PE ratio is 172.28 and the forward PE ratio is 10.73. BMRN's PEG ratio is 0.37.
| PE Ratio | 172.28 |
| Forward PE | 10.73 |
| PS Ratio | 3.71 |
| Forward PS | 2.95 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 16.06 |
| P/FCF Ratio | 17.12 |
| P/OCF Ratio | 14.74 |
| PEG Ratio | 0.37 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.74, with an EV/FCF ratio of 21.62.
| EV / Earnings | 218.75 |
| EV / Sales | 4.69 |
| EV / EBITDA | 24.74 |
| EV / EBIT | 31.94 |
| EV / FCF | 21.62 |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.66.
| Current Ratio | 2.39 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 6.41 |
| Debt / FCF | 5.69 |
| Interest Coverage | 5.98 |
Financial Efficiency
Return on equity (ROE) is 1.18% and return on invested capital (ROIC) is 3.24%.
| Return on Equity (ROE) | 1.18% |
| Return on Assets (ROA) | 3.26% |
| Return on Invested Capital (ROIC) | 3.24% |
| Return on Capital Employed (ROCE) | 4.97% |
| Weighted Average Cost of Capital (WACC) | 4.37% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | $22,655 |
| Employee Count | 3,221 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.07 |
Taxes
In the past 12 months, BMRN has paid $76.14 million in taxes.
| Income Tax | 76.14M |
| Effective Tax Rate | 51.06% |
Stock Price Statistics
The stock price has increased by +13.65% in the last 52 weeks. The beta is 0.23, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +13.65% |
| 50-Day Moving Average | 61.42 |
| 200-Day Moving Average | 57.51 |
| Relative Strength Index (RSI) | 52.96 |
| Average Volume (20 Days) | 2,308,162 |
Short Selling Information
The latest short interest is 12.50 million, so 6.46% of the outstanding shares have been sold short.
| Short Interest | 12.50M |
| Short Previous Month | 14.32M |
| Short % of Shares Out | 6.46% |
| Short % of Float | 6.50% |
| Short Ratio (days to cover) | 7.87 |
Income Statement
In the last 12 months, BMRN had revenue of $3.41 billion and earned $72.97 million in profits. Earnings per share was $0.38.
| Revenue | 3.41B |
| Gross Profit | 1.74B |
| Operating Income | 499.75M |
| Pretax Income | 149.11M |
| Net Income | 72.97M |
| EBITDA | 645.32M |
| EBIT | 499.75M |
| Earnings Per Share (EPS) | $0.38 |
Balance Sheet
The company has $874.01 million in cash and $4.20 billion in debt, with a net cash position of -$3.33 billion or -$17.19 per share.
| Cash & Cash Equivalents | 874.01M |
| Total Debt | 4.20B |
| Net Cash | -3.33B |
| Net Cash Per Share | -$17.19 |
| Equity (Book Value) | 6.32B |
| Book Value Per Share | 32.66 |
| Working Capital | 2.31B |
Cash Flow
In the last 12 months, operating cash flow was $857.09 million and capital expenditures -$118.91 million, giving a free cash flow of $738.18 million.
| Operating Cash Flow | 857.09M |
| Capital Expenditures | -118.91M |
| Depreciation & Amortization | 145.57M |
| Net Borrowing | 3.65B |
| Free Cash Flow | 738.18M |
| FCF Per Share | $3.81 |
Margins
Gross margin is 50.97%, with operating and profit margins of 14.67% and 2.14%.
| Gross Margin | 50.97% |
| Operating Margin | 14.67% |
| Pretax Margin | 4.38% |
| Profit Margin | 2.14% |
| EBITDA Margin | 18.94% |
| EBIT Margin | 14.67% |
| FCF Margin | 21.67% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.61% |
| Shareholder Yield | -0.61% |
| Earnings Yield | 0.58% |
| FCF Yield | 5.84% |
Analyst Forecast
The average price target for BMRN is $91.04, which is 39.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $91.04 |
| Price Target Difference | 39.44% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 14.28% |
| EPS Growth Forecast (3Y) | 33.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 1.9 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 4 |